ClearPoint Neuro, Inc. (CLPT) 10-Year Financial Performance & Capital Metrics

CLPT • • Industrial / General

HealthcareMedical DevicesNeurological & Neurostimulation DevicesNeurological Monitoring & Diagnostics

AboutClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Show more

Revenue $31M +31.0%
EBITDA -$18M +15.0%
Net Income -$19M +14.4%
EPS (Diluted) -0.70 +22.2%
Gross Margin 60.92% +7.2%
EBITDA Margin -56.84% +35.1%
Operating Margin -62.91% +32.9%
Net Margin -60.25% +34.7%
ROE -81.24% -6.8%
ROIC -142.21% -40.4%
Debt/Equity 0.14 -78.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 22.9%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 15.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y24.16%

5Y22.85%

3Y24.42%

TTM12.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-27.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-21.74%

ROCE

10Y Avg-82.1%

5Y Avg-42.36%

3Y Avg-48.32%

Latest-61.64%

Peer Comparison

Neurological Monitoring & Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
AMIXAutonomix Medical, Inc. Common Stock	3.59M	0.52	-0.08			-258.98%
CBLLCeriBell, Inc.	847.27M	22.84	-6.74	44.71%	-63.35%	-31.97%	0.11
NMTCNeuroOne Medical Technologies Corporation	45.32M	0.90	-9.99	250.35%	-39.63%	-50.98%	0.04
CLPTClearPoint Neuro, Inc.	435.81M	14.65	-20.93	31.04%	-67.4%	-145.77%	0.14

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.59M	5.75M	7.38M	7.35M	11.22M	12.83M	16.3M	20.55M	23.95M	31.39M
Revenue Growth %	0.27%	0.25%	0.28%	-0%	0.53%	0.14%	0.27%	0.26%	0.17%	0.31%
Cost of Goods Sold+	1.99M	2.64M	2.9M	2.43M	3.94M	3.71M	5.18M	7.02M	10.34M	12.27M
COGS % of Revenue	0.43%	0.46%	0.39%	0.33%	0.35%	0.29%	0.32%	0.34%	0.43%	0.39%
Gross Profit+	2.61M	3.11M	4.48M	4.92M	7.28M	9.12M	11.12M	13.53M	13.61M	19.12M
Gross Margin %	0.57%	0.54%	0.61%	0.67%	0.65%	0.71%	0.68%	0.66%	0.57%	0.61%
Gross Profit Growth %	0.55%	0.19%	0.44%	0.1%	0.48%	0.25%	0.22%	0.22%	0.01%	0.4%
Operating Expenses+	10.33M	10.6M	10.82M	10.17M	11.87M	15.34M	24.5M	29.86M	36.06M	38.87M
OpEx % of Revenue	2.25%	1.84%	1.47%	1.38%	1.06%	1.2%	1.5%	1.45%	1.51%	1.24%
Selling, General & Admin	8.37M	7.97M	8M	7.86M	9.06M	10.65M	15.22M	18.97M	24.35M	26.48M
SG&A % of Revenue	1.82%	1.39%	1.08%	1.07%	0.81%	0.83%	0.93%	0.92%	1.02%	0.84%
Research & Development	1.96M	2.63M	2.81M	2.31M	2.81M	4.69M	9.28M	10.89M	11.71M	12.39M
R&D % of Revenue	0.43%	0.46%	0.38%	0.31%	0.25%	0.37%	0.57%	0.53%	0.49%	0.39%
Other Operating Expenses	0	0	16.68K	364	0	0	0	0	0	0
Operating Income+	-8.97M	-7.49M	-6.34M	-5.25M	-4.59M	-6.22M	-13.37M	-16.33M	-22.45M	-19.75M
Operating Margin %	-1.95%	-1.3%	-0.86%	-0.71%	-0.41%	-0.48%	-0.82%	-0.79%	-0.94%	-0.63%
Operating Income Growth %	-0.69%	0.17%	0.15%	0.17%	0.12%	-0.35%	-1.15%	-0.22%	-0.37%	0.12%
EBITDA+	-8.76M	-7.33M	-6.22M	-5.14M	-4.34M	-5.67M	-12.68M	-15.55M	-20.99M	-17.84M
EBITDA Margin %	-1.91%	-1.28%	-0.84%	-0.7%	-0.39%	-0.44%	-0.78%	-0.76%	-0.88%	-0.57%
EBITDA Growth %	-0.77%	0.16%	0.15%	0.17%	0.15%	-0.31%	-1.24%	-0.23%	-0.35%	0.15%
D&A (Non-Cash Add-back)	211.95K	155.71K	116.45K	109.44K	251K	550K	692K	777K	1.46M	1.9M
EBIT	-7.19M	-7.02M	-6.29M	-5.18M	-4.58M	-5.34M	-13.44M	-16.35M	-22.45M	-19.75M
Net Interest Income+	-1.25M	-1.05M	-872.93K	-980.38K	-955K	-1.44M	-973K	-81K	386K	872K
Interest Income	16.45K	8.81K	0	0	0	0	0	0	386K	872K
Interest Expense	1.26M	1.06M	872.93K	980.38K	955K	1.44M	973K	81K	0	0
Other Income/Expense	524.86K	-581.16K	-831.52K	-915.7K	-946K	-562K	-1.04M	-103K	357K	832K
Pretax Income+	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Pretax Margin %	-1.84%	-1.4%	-0.97%	-0.84%	-0.49%	-0.53%	-0.88%	-0.8%	-0.92%	-0.6%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Net Margin %	-1.84%	-1.4%	-0.97%	-0.84%	-0.49%	-0.53%	-0.88%	-0.8%	-0.92%	-0.6%
Net Income Growth %	-0.87%	0.04%	0.11%	0.14%	0.1%	-0.22%	-1.12%	-0.14%	-0.34%	0.14%
Net Income (Continuing)	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.48	-2.93	-0.93	-0.56	-0.49	-0.43	-0.69	-0.68	-0.90	-0.70
EPS Growth %	-0.46%	0.35%	0.68%	0.4%	0.13%	0.12%	-0.6%	0.01%	-0.32%	0.22%
EPS (Basic)	-4.48	-2.93	-0.93	-0.56	-0.49	-0.43	-0.69	-0.68	-0.90	-0.70
Diluted Shares Outstanding	1.88M	2.75M	7.74M	10.93M	13.16M	15.85M	20.73M	24.18M	24.61M	27.03M
Basic Shares Outstanding	1.88M	2.75M	7.74M	10.93M	13.16M	15.85M	20.73M	24.18M	24.61M	27.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.53M	6.09M	12.75M	6.65M	10.38M	25.46M	61.89M	51.18M	36.17M	33.36M
Cash & Short-Term Investments	5.41M	3.32M	9.29M	3.1M	5.7M	20.1M	54.11M	37.49M	23.14M	20.1M
Cash Only	5.41M	3.32M	9.29M	3.1M	5.7M	20.1M	54.11M	27.61M	23.14M	20.1M
Short-Term Investments	0	0	0	0	0	0	0	9.87M	0	0
Accounts Receivable	1.22M	865.94K	949.41K	1.23M	1.09M	1.88M	2.34M	2.67M	3.94M	4.71M
Days Sales Outstanding	96.77	54.97	46.96	61.25	35.47	53.52	52.33	47.33	60.09	54.8
Inventory	1.81M	1.77M	2.31M	2.11M	3.24M	3.24M	4.94M	9.3M	7.91M	6.86M
Days Inventory Outstanding	331.99	244.24	291.39	315.93	300	318.65	348.22	483.7	279.23	204.19
Other Current Assets	0	0	0	0	0	0	0	1.72M	0	1.68M
Total Non-Current Assets+	1.57M	1.32M	1.15M	1.2M	1.54M	4.06M	3.69M	4.31M	6.49M	5.83M
Property, Plant & Equipment	440.61K	328.25K	267.67K	377.71K	821K	3.06M	2.78M	2.7M	4.95M	5.09M
Fixed Asset Turnover	10.43x	17.52x	27.57x	19.47x	13.66x	4.20x	5.86x	7.61x	4.84x	6.17x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	353K	265K	1.03M	1.04M	484K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.13M	987.54K	883.54K	824.44K	722K	648K	644K	581K	495K	251K
Total Assets+	10.1M	7.4M	13.9M	7.86M	11.93M	29.52M	65.58M	55.49M	42.66M	39.19M
Asset Turnover	0.45x	0.78x	0.53x	0.94x	0.94x	0.43x	0.25x	0.37x	0.56x	0.80x
Asset Growth %	-0.25%	-0.27%	0.88%	-0.43%	0.52%	1.47%	1.22%	-0.15%	-0.23%	-0.08%
Total Current Liabilities+	7.65M	3.02M	4.4M	2.01M	3.83M	3.2M	4.75M	6.79M	7.43M	10.35M
Accounts Payable	697.81K	1.55M	759.45K	500.93K	966K	300K	427K	272K	393K	1.34M
Days Payables Outstanding	128.14	213.65	95.62	75.15	89.44	29.52	30.11	14.14	13.87	39.87
Short-Term Debt	4.22M	0	2M	0	0	0	0	0	0	0
Deferred Revenue (Current)	116.01K	223.12K	256.18K	350.96K	1000K	562K	678K	1000K	1000K	1000K
Other Current Liabilities	2.06M	581.6K	575.95K	741.8K	1.41M	1.59M	2.6M	2.82M	2.95M	4.88M
Current Ratio	1.11x	2.02x	2.90x	3.31x	2.71x	7.96x	13.02x	7.54x	4.87x	3.22x
Quick Ratio	0.88x	1.43x	2.37x	2.27x	1.86x	6.95x	11.98x	6.17x	3.80x	2.56x
Cash Conversion Cycle	300.62	85.56	242.72	302.03	246.02	342.64	370.44	516.89	325.45	219.12
Total Non-Current Liabilities+	4.43M	5.14M	3.67M	4.34M	3.51M	23.94M	12.04M	11.81M	14.06M	3.45M
Long-Term Debt	3.72M	4.49M	2.92M	3.48M	2.07M	21.28M	9.84M	9.89M	9.95M	0
Capital Lease Obligations	0	0	0	0	277K	2.45M	1.94M	1.53M	3.57M	3.01M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	542.5K	647.5K	752.5K	997.7K	960K	0	0	0	0	0
Total Liabilities	12.08M	8.16M	8.07M	6.35M	7.34M	27.14M	16.79M	18.6M	21.49M	13.8M
Total Debt+	8.11M	4.49M	4.92M	3.48M	2.46M	24.12M	12.28M	11.99M	13.94M	3.57M
Net Debt	2.7M	1.18M	-4.37M	379.51K	-3.23M	4.02M	-41.83M	-15.63M	-9.2M	-16.54M
Debt / Equity	-	-	0.84x	2.30x	0.54x	10.15x	0.25x	0.32x	0.66x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.11x	-7.06x	-7.26x	-5.35x	-4.81x	-4.31x	-13.75x	-201.63x	-	-
Total Equity+	-1.98M	-756.07K	5.83M	1.51M	4.59M	2.38M	48.79M	36.89M	21.17M	25.39M
Equity Growth %	-18.75%	0.62%	8.71%	-0.74%	2.04%	-0.48%	19.52%	-0.24%	-0.43%	0.2%
Book Value per Share	-1.05	-0.27	0.75	0.14	0.35	0.15	2.35	1.53	0.86	0.94
Total Shareholders' Equity	-1.98M	-756.07K	5.83M	1.51M	4.59M	2.38M	48.79M	36.89M	21.17M	25.39M
Common Stock	913.81K	36.22K	106.94K	110.18K	152K	170K	237K	246K	247K	276K
Retained Earnings	-85.73M	-93.87M	-101.04M	-107.2M	-112.74M	-119.52M	-133.93M	-150.37M	-172.46M	-191.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.73M	-1.71M	-1.67M	-1.72M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.64M	-5.82M	-5.99M	-4.63M	-2.85M	-7.81M	-12.7M	-16.17M	-13.72M	-8.95M
Operating CF Margin %	-1.88%	-1.01%	-0.81%	-0.63%	-0.25%	-0.61%	-0.78%	-0.79%	-0.57%	-0.29%
Operating CF Growth %	-0.19%	0.33%	-0.03%	0.23%	0.38%	-1.74%	-0.63%	-0.27%	0.15%	0.35%
Net Income	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Depreciation & Amortization	211.95K	155.71K	116.45K	109.44K	250.56K	553K	692K	777K	1.51M	1.9M
Stock-Based Compensation	1.68M	959.59K	1.25M	1.23M	799.11K	1.09M	2.08M	0	6.08M	6.91M
Deferred Taxes	-1.54M	-252.34K	-24.18K	-64.32K	0	-896K	202K	0	0	0
Other Non-Cash Items	617.13K	714.68K	928.39K	640.03K	729.29K	893K	425K	3.78M	2.18M	-245K
Working Capital Changes	-1.16M	672.22K	-1.09M	-383.65K	911.32K	-2.67M	-1.68M	-4.29M	-1.4M	1.4M
Change in Receivables	-749.09K	352.1K	-83.47K	-284.48K	143.98K	-791K	627K	-211K	-1.8M	-1.21M
Change in Inventory	68.63K	72.34K	-469.92K	122.22K	-1.02M	-25K	-1.71M	-4.42M	1.25M	743K
Change in Payables	-436.42M	178.42M	-512.36M	-316.18K	928.16K	-453K	-762K	1.59M	0	3.1M
Cash from Investing+	-76.88K	-101K	-26.75K	-63.49K	-160.19K	-482K	-168K	-10.74M	8.95M	-275K
Capital Expenditures	-76.88K	-101K	-26.75K	-63.49K	-160.19K	-482K	-168K	-1.15M	-717K	-275K
CapEx % of Revenue	0.02%	0.02%	0%	0.01%	0.01%	0.04%	0.01%	0.06%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	9.67M	0
Cash from Financing+	4.88M	3.83M	11.99M	-1.49M	5.6M	22.69M	46.88M	409K	296K	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-4.76K	0	505.38K	313.29K	1K	90K	-336K	506K	40K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.71M	-5.92M	-6.02M	-4.69M	-3.01M	-8.29M	-12.87M	-16.42M	-14.44M	-9.22M
FCF Margin %	-1.9%	-1.03%	-0.82%	-0.64%	-0.27%	-0.65%	-0.79%	-0.8%	-0.6%	-0.29%
FCF Growth %	-0.19%	0.32%	-0.02%	0.22%	0.36%	-1.75%	-0.55%	-0.28%	0.12%	0.36%
FCF per Share	-4.62	-2.15	-0.78	-0.43	-0.23	-0.52	-0.62	-0.68	-0.59	-0.34
FCF Conversion (FCF/Net Income)	1.02x	0.72x	0.84x	0.75x	0.51x	1.15x	0.88x	0.98x	0.62x	0.47x
Interest Paid	0	0	0	0	0	0	0	0	743K	480K
Taxes Paid	0	0	0	0	0	0	0	0	0	62K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-282.59%	-167.95%	-181.73%	-194.8%	-56.33%	-38.37%	-76.09%	-81.24%
Return on Invested Capital (ROIC)	-	-982.69%	-506.35%	-235.15%	-212.39%	-120.36%	-150.16%	-86.81%	-101.31%	-142.21%
Gross Margin	56.74%	54.03%	60.72%	66.91%	64.86%	71.09%	68.24%	65.84%	56.83%	60.92%
Net Margin	-183.91%	-140.36%	-97.12%	-83.82%	-49.39%	-52.86%	-88.41%	-79.97%	-92.21%	-60.25%
Debt / Equity	-	-	0.84x	2.30x	0.54x	10.15x	0.25x	0.32x	0.66x	0.14x
Interest Coverage	-7.11x	-7.06x	-7.26x	-5.35x	-4.81x	-4.31x	-13.75x	-201.63x	-	-
FCF Conversion	1.02x	0.72x	0.84x	0.75x	0.51x	1.15x	0.88x	0.98x	0.62x	0.47x
Revenue Growth	27.46%	25.15%	28.35%	-0.36%	52.54%	14.37%	27.05%	26.09%	16.56%	31.04%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Biologics and Drug Delivery Revenue	-	-	5.04M	6.79M	9.12M	13.6M	17.31M
Biologics and Drug Delivery Revenue Growth	-	-	-	34.74%	34.22%	49.14%	27.26%
Biologics and Drug Delivery - Disposable Products	-	-	-	3.35M	3.69M	2.15M	5.61M
Biologics and Drug Delivery - Disposable Products Growth	-	-	-	-	10.05%	-41.63%	160.26%
Capital Equipment and Software Revenue	-	-	1.49M	1.43M	2.31M	1.83M	3.79M
Capital Equipment and Software Revenue Growth	-	-	-	-3.83%	60.99%	-20.55%	107.04%
Capital Equipment and Software - Systems and Software Products	-	-	-	864K	1.51M	860K	2.73M
Capital Equipment and Software - Systems and Software Products Growth	-	-	-	-	75.00%	-43.12%	218.02%
Capital Equipment and Software - Services	-	-	-	569K	795K	973K	1.06M
Capital Equipment and Software - Services Growth	-	-	-	-	39.72%	22.39%	8.94%
Functional Neurosurgery Navigation and Therapy	-	-	-	8.07M	9.12M	8.52M	-
Functional Neurosurgery Navigation and Therapy Growth	-	-	-	-	13.05%	-6.62%	-
Functional Neurosurgery Navigation and Therapy - Disposable Products	-	-	-	7.7M	7.59M	7.59M	-
Functional Neurosurgery Navigation and Therapy - Disposable Products Growth	-	-	-	-	-1.42%	0.03%	-
Functional Neurosurgery Navigation and Therapy - Services	-	-	-	375K	1.54M	931K	-
Functional Neurosurgery Navigation and Therapy - Services Growth	-	-	-	-	309.87%	-39.43%	-
Biologics and Drug Delivery - Services	-	-	-	3.44M	-	-	-
Biologics and Drug Delivery - Services Growth	-	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue	-	1.1M	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Growth	-	-	-	-	-	-	-
Capital Equipment-Related Service Revenue	-	228K	-	-	-	-	-
Capital Equipment-Related Service Revenue Growth	-	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member]	303.91K	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member] Growth	-	-	-	-	-	-	-
Capital Equipment-Related Service Revenue Member]	142.6K	-	-	-	-	-	-
Capital Equipment-Related Service Revenue Member] Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ClearPoint Neuro, Inc. (CLPT) reported $34.3M in revenue for fiscal year 2024. This represents a 799% increase from $3.8M in 2011.

ClearPoint Neuro, Inc. (CLPT) grew revenue by 31.0% over the past year. This is strong growth.

ClearPoint Neuro, Inc. (CLPT) reported a net loss of $23.1M for fiscal year 2024.

Dividend & Returns

ClearPoint Neuro, Inc. (CLPT) has a return on equity (ROE) of -81.2%. Negative ROE indicates the company is unprofitable.

ClearPoint Neuro, Inc. (CLPT) had negative free cash flow of $13.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

ClearPoint Neuro, Inc. (CLPT) 10-Year Financial Performance & Capital Metrics

CLPT • • Industrial / General

HealthcareMedical DevicesNeurological & Neurostimulation DevicesNeurological Monitoring & Diagnostics

Revenue $31M +31.0%
EBITDA -$18M +15.0%
Net Income -$19M +14.4%
EPS (Diluted) -0.70 +22.2%
Gross Margin 60.92% +7.2%
EBITDA Margin -56.84% +35.1%
Operating Margin -62.91% +32.9%
Net Margin -60.25% +34.7%
ROE -81.24% -6.8%
ROIC -142.21% -40.4%
Debt/Equity 0.14 -78.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 22.9%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Expensive at 15.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y24.16%

5Y22.85%

3Y24.42%

TTM12.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-27.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-21.74%

ROCE

10Y Avg-82.1%

5Y Avg-42.36%

3Y Avg-48.32%

Latest-61.64%

Peer Comparison

Neurological Monitoring & Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
AMIXAutonomix Medical, Inc. Common Stock	3.59M	0.52	-0.08			-258.98%
CBLLCeriBell, Inc.	847.27M	22.84	-6.74	44.71%	-63.35%	-31.97%	0.11
NMTCNeuroOne Medical Technologies Corporation	45.32M	0.90	-9.99	250.35%	-39.63%	-50.98%	0.04
CLPTClearPoint Neuro, Inc.	435.81M	14.65	-20.93	31.04%	-67.4%	-145.77%	0.14

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.59M	5.75M	7.38M	7.35M	11.22M	12.83M	16.3M	20.55M	23.95M	31.39M
Revenue Growth %	0.27%	0.25%	0.28%	-0%	0.53%	0.14%	0.27%	0.26%	0.17%	0.31%
Cost of Goods Sold+	1.99M	2.64M	2.9M	2.43M	3.94M	3.71M	5.18M	7.02M	10.34M	12.27M
COGS % of Revenue	0.43%	0.46%	0.39%	0.33%	0.35%	0.29%	0.32%	0.34%	0.43%	0.39%
Gross Profit+	2.61M	3.11M	4.48M	4.92M	7.28M	9.12M	11.12M	13.53M	13.61M	19.12M
Gross Margin %	0.57%	0.54%	0.61%	0.67%	0.65%	0.71%	0.68%	0.66%	0.57%	0.61%
Gross Profit Growth %	0.55%	0.19%	0.44%	0.1%	0.48%	0.25%	0.22%	0.22%	0.01%	0.4%
Operating Expenses+	10.33M	10.6M	10.82M	10.17M	11.87M	15.34M	24.5M	29.86M	36.06M	38.87M
OpEx % of Revenue	2.25%	1.84%	1.47%	1.38%	1.06%	1.2%	1.5%	1.45%	1.51%	1.24%
Selling, General & Admin	8.37M	7.97M	8M	7.86M	9.06M	10.65M	15.22M	18.97M	24.35M	26.48M
SG&A % of Revenue	1.82%	1.39%	1.08%	1.07%	0.81%	0.83%	0.93%	0.92%	1.02%	0.84%
Research & Development	1.96M	2.63M	2.81M	2.31M	2.81M	4.69M	9.28M	10.89M	11.71M	12.39M
R&D % of Revenue	0.43%	0.46%	0.38%	0.31%	0.25%	0.37%	0.57%	0.53%	0.49%	0.39%
Other Operating Expenses	0	0	16.68K	364	0	0	0	0	0	0
Operating Income+	-8.97M	-7.49M	-6.34M	-5.25M	-4.59M	-6.22M	-13.37M	-16.33M	-22.45M	-19.75M
Operating Margin %	-1.95%	-1.3%	-0.86%	-0.71%	-0.41%	-0.48%	-0.82%	-0.79%	-0.94%	-0.63%
Operating Income Growth %	-0.69%	0.17%	0.15%	0.17%	0.12%	-0.35%	-1.15%	-0.22%	-0.37%	0.12%
EBITDA+	-8.76M	-7.33M	-6.22M	-5.14M	-4.34M	-5.67M	-12.68M	-15.55M	-20.99M	-17.84M
EBITDA Margin %	-1.91%	-1.28%	-0.84%	-0.7%	-0.39%	-0.44%	-0.78%	-0.76%	-0.88%	-0.57%
EBITDA Growth %	-0.77%	0.16%	0.15%	0.17%	0.15%	-0.31%	-1.24%	-0.23%	-0.35%	0.15%
D&A (Non-Cash Add-back)	211.95K	155.71K	116.45K	109.44K	251K	550K	692K	777K	1.46M	1.9M
EBIT	-7.19M	-7.02M	-6.29M	-5.18M	-4.58M	-5.34M	-13.44M	-16.35M	-22.45M	-19.75M
Net Interest Income+	-1.25M	-1.05M	-872.93K	-980.38K	-955K	-1.44M	-973K	-81K	386K	872K
Interest Income	16.45K	8.81K	0	0	0	0	0	0	386K	872K
Interest Expense	1.26M	1.06M	872.93K	980.38K	955K	1.44M	973K	81K	0	0
Other Income/Expense	524.86K	-581.16K	-831.52K	-915.7K	-946K	-562K	-1.04M	-103K	357K	832K
Pretax Income+	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Pretax Margin %	-1.84%	-1.4%	-0.97%	-0.84%	-0.49%	-0.53%	-0.88%	-0.8%	-0.92%	-0.6%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Net Margin %	-1.84%	-1.4%	-0.97%	-0.84%	-0.49%	-0.53%	-0.88%	-0.8%	-0.92%	-0.6%
Net Income Growth %	-0.87%	0.04%	0.11%	0.14%	0.1%	-0.22%	-1.12%	-0.14%	-0.34%	0.14%
Net Income (Continuing)	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.48	-2.93	-0.93	-0.56	-0.49	-0.43	-0.69	-0.68	-0.90	-0.70
EPS Growth %	-0.46%	0.35%	0.68%	0.4%	0.13%	0.12%	-0.6%	0.01%	-0.32%	0.22%
EPS (Basic)	-4.48	-2.93	-0.93	-0.56	-0.49	-0.43	-0.69	-0.68	-0.90	-0.70
Diluted Shares Outstanding	1.88M	2.75M	7.74M	10.93M	13.16M	15.85M	20.73M	24.18M	24.61M	27.03M
Basic Shares Outstanding	1.88M	2.75M	7.74M	10.93M	13.16M	15.85M	20.73M	24.18M	24.61M	27.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.53M	6.09M	12.75M	6.65M	10.38M	25.46M	61.89M	51.18M	36.17M	33.36M
Cash & Short-Term Investments	5.41M	3.32M	9.29M	3.1M	5.7M	20.1M	54.11M	37.49M	23.14M	20.1M
Cash Only	5.41M	3.32M	9.29M	3.1M	5.7M	20.1M	54.11M	27.61M	23.14M	20.1M
Short-Term Investments	0	0	0	0	0	0	0	9.87M	0	0
Accounts Receivable	1.22M	865.94K	949.41K	1.23M	1.09M	1.88M	2.34M	2.67M	3.94M	4.71M
Days Sales Outstanding	96.77	54.97	46.96	61.25	35.47	53.52	52.33	47.33	60.09	54.8
Inventory	1.81M	1.77M	2.31M	2.11M	3.24M	3.24M	4.94M	9.3M	7.91M	6.86M
Days Inventory Outstanding	331.99	244.24	291.39	315.93	300	318.65	348.22	483.7	279.23	204.19
Other Current Assets	0	0	0	0	0	0	0	1.72M	0	1.68M
Total Non-Current Assets+	1.57M	1.32M	1.15M	1.2M	1.54M	4.06M	3.69M	4.31M	6.49M	5.83M
Property, Plant & Equipment	440.61K	328.25K	267.67K	377.71K	821K	3.06M	2.78M	2.7M	4.95M	5.09M
Fixed Asset Turnover	10.43x	17.52x	27.57x	19.47x	13.66x	4.20x	5.86x	7.61x	4.84x	6.17x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	353K	265K	1.03M	1.04M	484K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.13M	987.54K	883.54K	824.44K	722K	648K	644K	581K	495K	251K
Total Assets+	10.1M	7.4M	13.9M	7.86M	11.93M	29.52M	65.58M	55.49M	42.66M	39.19M
Asset Turnover	0.45x	0.78x	0.53x	0.94x	0.94x	0.43x	0.25x	0.37x	0.56x	0.80x
Asset Growth %	-0.25%	-0.27%	0.88%	-0.43%	0.52%	1.47%	1.22%	-0.15%	-0.23%	-0.08%
Total Current Liabilities+	7.65M	3.02M	4.4M	2.01M	3.83M	3.2M	4.75M	6.79M	7.43M	10.35M
Accounts Payable	697.81K	1.55M	759.45K	500.93K	966K	300K	427K	272K	393K	1.34M
Days Payables Outstanding	128.14	213.65	95.62	75.15	89.44	29.52	30.11	14.14	13.87	39.87
Short-Term Debt	4.22M	0	2M	0	0	0	0	0	0	0
Deferred Revenue (Current)	116.01K	223.12K	256.18K	350.96K	1000K	562K	678K	1000K	1000K	1000K
Other Current Liabilities	2.06M	581.6K	575.95K	741.8K	1.41M	1.59M	2.6M	2.82M	2.95M	4.88M
Current Ratio	1.11x	2.02x	2.90x	3.31x	2.71x	7.96x	13.02x	7.54x	4.87x	3.22x
Quick Ratio	0.88x	1.43x	2.37x	2.27x	1.86x	6.95x	11.98x	6.17x	3.80x	2.56x
Cash Conversion Cycle	300.62	85.56	242.72	302.03	246.02	342.64	370.44	516.89	325.45	219.12
Total Non-Current Liabilities+	4.43M	5.14M	3.67M	4.34M	3.51M	23.94M	12.04M	11.81M	14.06M	3.45M
Long-Term Debt	3.72M	4.49M	2.92M	3.48M	2.07M	21.28M	9.84M	9.89M	9.95M	0
Capital Lease Obligations	0	0	0	0	277K	2.45M	1.94M	1.53M	3.57M	3.01M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	542.5K	647.5K	752.5K	997.7K	960K	0	0	0	0	0
Total Liabilities	12.08M	8.16M	8.07M	6.35M	7.34M	27.14M	16.79M	18.6M	21.49M	13.8M
Total Debt+	8.11M	4.49M	4.92M	3.48M	2.46M	24.12M	12.28M	11.99M	13.94M	3.57M
Net Debt	2.7M	1.18M	-4.37M	379.51K	-3.23M	4.02M	-41.83M	-15.63M	-9.2M	-16.54M
Debt / Equity	-	-	0.84x	2.30x	0.54x	10.15x	0.25x	0.32x	0.66x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-7.11x	-7.06x	-7.26x	-5.35x	-4.81x	-4.31x	-13.75x	-201.63x	-	-
Total Equity+	-1.98M	-756.07K	5.83M	1.51M	4.59M	2.38M	48.79M	36.89M	21.17M	25.39M
Equity Growth %	-18.75%	0.62%	8.71%	-0.74%	2.04%	-0.48%	19.52%	-0.24%	-0.43%	0.2%
Book Value per Share	-1.05	-0.27	0.75	0.14	0.35	0.15	2.35	1.53	0.86	0.94
Total Shareholders' Equity	-1.98M	-756.07K	5.83M	1.51M	4.59M	2.38M	48.79M	36.89M	21.17M	25.39M
Common Stock	913.81K	36.22K	106.94K	110.18K	152K	170K	237K	246K	247K	276K
Retained Earnings	-85.73M	-93.87M	-101.04M	-107.2M	-112.74M	-119.52M	-133.93M	-150.37M	-172.46M	-191.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.73M	-1.71M	-1.67M	-1.72M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.64M	-5.82M	-5.99M	-4.63M	-2.85M	-7.81M	-12.7M	-16.17M	-13.72M	-8.95M
Operating CF Margin %	-1.88%	-1.01%	-0.81%	-0.63%	-0.25%	-0.61%	-0.78%	-0.79%	-0.57%	-0.29%
Operating CF Growth %	-0.19%	0.33%	-0.03%	0.23%	0.38%	-1.74%	-0.63%	-0.27%	0.15%	0.35%
Net Income	-8.45M	-8.07M	-7.17M	-6.16M	-5.54M	-6.78M	-14.41M	-16.43M	-22.09M	-18.91M
Depreciation & Amortization	211.95K	155.71K	116.45K	109.44K	250.56K	553K	692K	777K	1.51M	1.9M
Stock-Based Compensation	1.68M	959.59K	1.25M	1.23M	799.11K	1.09M	2.08M	0	6.08M	6.91M
Deferred Taxes	-1.54M	-252.34K	-24.18K	-64.32K	0	-896K	202K	0	0	0
Other Non-Cash Items	617.13K	714.68K	928.39K	640.03K	729.29K	893K	425K	3.78M	2.18M	-245K
Working Capital Changes	-1.16M	672.22K	-1.09M	-383.65K	911.32K	-2.67M	-1.68M	-4.29M	-1.4M	1.4M
Change in Receivables	-749.09K	352.1K	-83.47K	-284.48K	143.98K	-791K	627K	-211K	-1.8M	-1.21M
Change in Inventory	68.63K	72.34K	-469.92K	122.22K	-1.02M	-25K	-1.71M	-4.42M	1.25M	743K
Change in Payables	-436.42M	178.42M	-512.36M	-316.18K	928.16K	-453K	-762K	1.59M	0	3.1M
Cash from Investing+	-76.88K	-101K	-26.75K	-63.49K	-160.19K	-482K	-168K	-10.74M	8.95M	-275K
Capital Expenditures	-76.88K	-101K	-26.75K	-63.49K	-160.19K	-482K	-168K	-1.15M	-717K	-275K
CapEx % of Revenue	0.02%	0.02%	0%	0.01%	0.01%	0.04%	0.01%	0.06%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	9.67M	0
Cash from Financing+	4.88M	3.83M	11.99M	-1.49M	5.6M	22.69M	46.88M	409K	296K	6.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-4.76K	0	505.38K	313.29K	1K	90K	-336K	506K	40K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.71M	-5.92M	-6.02M	-4.69M	-3.01M	-8.29M	-12.87M	-16.42M	-14.44M	-9.22M
FCF Margin %	-1.9%	-1.03%	-0.82%	-0.64%	-0.27%	-0.65%	-0.79%	-0.8%	-0.6%	-0.29%
FCF Growth %	-0.19%	0.32%	-0.02%	0.22%	0.36%	-1.75%	-0.55%	-0.28%	0.12%	0.36%
FCF per Share	-4.62	-2.15	-0.78	-0.43	-0.23	-0.52	-0.62	-0.68	-0.59	-0.34
FCF Conversion (FCF/Net Income)	1.02x	0.72x	0.84x	0.75x	0.51x	1.15x	0.88x	0.98x	0.62x	0.47x
Interest Paid	0	0	0	0	0	0	0	0	743K	480K
Taxes Paid	0	0	0	0	0	0	0	0	0	62K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-282.59%	-167.95%	-181.73%	-194.8%	-56.33%	-38.37%	-76.09%	-81.24%
Return on Invested Capital (ROIC)	-	-982.69%	-506.35%	-235.15%	-212.39%	-120.36%	-150.16%	-86.81%	-101.31%	-142.21%
Gross Margin	56.74%	54.03%	60.72%	66.91%	64.86%	71.09%	68.24%	65.84%	56.83%	60.92%
Net Margin	-183.91%	-140.36%	-97.12%	-83.82%	-49.39%	-52.86%	-88.41%	-79.97%	-92.21%	-60.25%
Debt / Equity	-	-	0.84x	2.30x	0.54x	10.15x	0.25x	0.32x	0.66x	0.14x
Interest Coverage	-7.11x	-7.06x	-7.26x	-5.35x	-4.81x	-4.31x	-13.75x	-201.63x	-	-
FCF Conversion	1.02x	0.72x	0.84x	0.75x	0.51x	1.15x	0.88x	0.98x	0.62x	0.47x
Revenue Growth	27.46%	25.15%	28.35%	-0.36%	52.54%	14.37%	27.05%	26.09%	16.56%	31.04%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Biologics and Drug Delivery Revenue	-	-	5.04M	6.79M	9.12M	13.6M	17.31M
Biologics and Drug Delivery Revenue Growth	-	-	-	34.74%	34.22%	49.14%	27.26%
Biologics and Drug Delivery - Disposable Products	-	-	-	3.35M	3.69M	2.15M	5.61M
Biologics and Drug Delivery - Disposable Products Growth	-	-	-	-	10.05%	-41.63%	160.26%
Capital Equipment and Software Revenue	-	-	1.49M	1.43M	2.31M	1.83M	3.79M
Capital Equipment and Software Revenue Growth	-	-	-	-3.83%	60.99%	-20.55%	107.04%
Capital Equipment and Software - Systems and Software Products	-	-	-	864K	1.51M	860K	2.73M
Capital Equipment and Software - Systems and Software Products Growth	-	-	-	-	75.00%	-43.12%	218.02%
Capital Equipment and Software - Services	-	-	-	569K	795K	973K	1.06M
Capital Equipment and Software - Services Growth	-	-	-	-	39.72%	22.39%	8.94%
Functional Neurosurgery Navigation and Therapy	-	-	-	8.07M	9.12M	8.52M	-
Functional Neurosurgery Navigation and Therapy Growth	-	-	-	-	13.05%	-6.62%	-
Functional Neurosurgery Navigation and Therapy - Disposable Products	-	-	-	7.7M	7.59M	7.59M	-
Functional Neurosurgery Navigation and Therapy - Disposable Products Growth	-	-	-	-	-1.42%	0.03%	-
Functional Neurosurgery Navigation and Therapy - Services	-	-	-	375K	1.54M	931K	-
Functional Neurosurgery Navigation and Therapy - Services Growth	-	-	-	-	309.87%	-39.43%	-
Biologics and Drug Delivery - Services	-	-	-	3.44M	-	-	-
Biologics and Drug Delivery - Services Growth	-	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue	-	1.1M	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Growth	-	-	-	-	-	-	-
Capital Equipment-Related Service Revenue	-	228K	-	-	-	-	-
Capital Equipment-Related Service Revenue Growth	-	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member]	303.91K	-	-	-	-	-	-
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member] Growth	-	-	-	-	-	-	-
Capital Equipment-Related Service Revenue Member]	142.6K	-	-	-	-	-	-
Capital Equipment-Related Service Revenue Member] Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ClearPoint Neuro, Inc. (CLPT) reported $34.3M in revenue for fiscal year 2024. This represents a 799% increase from $3.8M in 2011.

ClearPoint Neuro, Inc. (CLPT) grew revenue by 31.0% over the past year. This is strong growth.

ClearPoint Neuro, Inc. (CLPT) reported a net loss of $23.1M for fiscal year 2024.

Dividend & Returns

ClearPoint Neuro, Inc. (CLPT) has a return on equity (ROE) of -81.2%. Negative ROE indicates the company is unprofitable.

ClearPoint Neuro, Inc. (CLPT) had negative free cash flow of $13.8M in fiscal year 2024, likely due to heavy capital investments.